PFE's bullish support has already been observed at the $25s, with the worst seemingly well behind us. Its core portfolio continues to generate robust growth at +14% YoY in FQ2'24 (excluding Comirnaty and Paxlovid), with Seagen's therapies already at $2.92B in annualized revenues. FY2025 is likely to bring forth an improved YoY comparison as well, with PFE's 3Y cost optimization program expected to boost their gross/ operating margins to pre-pandemic levels.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Stock market prices don't tell you everything, and that's certainly true with these businesses. Pfizer is paving the way to future growth, but investors might need to be patient.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
Major drugmakers Pfizer and Eli Lilly made major direct-to-consumer announcements. While Walgreens was named as a partner for Pfizer's new direct health platform, it stands to potentially lose out on retail drug sales.
A brand new round of Covid shots from Pfizer and Moderna is about to reach Americans. Meanwhile, CNBC tested out Dexcom's new CGM Stelo.
Pfizer Inc is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses.
Pfizer Inc. on Tuesday unveiled a new online platform designed to help simplify and coordinate healthcare for consumers, adding momentum to an emerging trend in big pharma that has drawn criticism from some provider groups and policy experts.
One of Pfizer's vaccine programs failed to demonstrate its utility. Its competitors had the same issue with their programs.
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
It is never too early to start your investment journey.